Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARKOV: Evolocumab in Patients with Reduced FFR
NCT03851263Phase 4Withdrawn
- Sponsor
- ECRI
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of evolocumab in coronary artery disease (CAD), sponsored by ECRI. Planned start Aug 2019; status: withdrawn.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03851263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851263.